Browse > Article

Immunohistochemical Expression of Galectin-3, Cytokeratin 19 and HBME-1 in Papillary Microcarcinoma of the Thyroid Gland  

Kim, Jin-Hwan (Department of Pathology, Keimyung University School of Medicine)
Lee, Sang-Sook (Department of Pathology, Keimyung University School of Medicine)
Publication Information
Korean Journal of Head & Neck Oncology / v.23, no.2, 2007 , pp. 133-137 More about this Journal
Abstract
With the wide use of ultrasonography and fine needle aspiration of the thyroid gland, the incidence of papillary microcarcinoma of the thyroid gland is rapidly increasing nowadays. To improve the diagnostic accuracy of histopathologic findings of papillary thyroid carcinoma, various molecular markers have been used recently. We analysed the expression of galectin-3, cytokeratin 19 and HBME-1, using immunohistochemical technique in 37 cases of papillary microcarcinoma of the thyroid gland to evaluate the diagnostic value of these molecular markers. Immunohistochemically, galectin-3 expression was found in 37 cases of papillary microcarcinoma. Its localization was mostly cytoplasmic. Cytokeratin 19 expression was found in 36 cases. It was mostly localized to the cytoplasm and membrane. HBME-1 expression was found in all cases. Its localization was plasma membrane. The expression of these three molecular markers was negative in the adjacent normal thyroid tissue and accompanying benign lesions, although there are scattered foci of incomplete positive staining in cases of Hashimoto's thyroiditis. Our findings suggest that the immunohistochemical staining using antibodies for galectin-3, cytokeratin 19 and HBME-1 is an useful adjunctive method for the histopathological diagnosis of a papillary microcarcinoma of the thyroid gland.
Keywords
Papillary microcarcinoma; Thyroid; Galectin-3; Cytokeratin 19; HBME-1;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Piersanti M, Ezzat S, Asa SL: Controversies in papillary microcarcinoma of the thyroid. Endocrine Pathol. 2003;l4:183-192   DOI   ScienceOn
2 Park MI, Kang DY: Usefulness of galectin-3, cytokertin 19, p53, and Ki-67 for the differential diagnosis of thyroid tumors. Korean J Pathol. 2006;40:86-92
3 Hapke M, Dehner LP: The optically clear nucleus. A reliable sign of papillary carcinoma of the thyroid? Am J Surg Pathol. 1979;3:31-38   DOI   ScienceOn
4 Xu XC, El Naggar AK, Lotan R: Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol. 1995;147:815-822
5 Beesley MF, McLaren KM: Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002;41:236-243   DOI   ScienceOn
6 Nikiforova MN, Lynch RA, Biddinger PW, et al: RAS point mutations and PAX8-PPAR rearrangement in thyroid tumors. Evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88:2318-2326   DOI
7 van Hoeven KH, Kovatich AJ, Miettinen M: Immunocytochemical evaluation of HBME-1, CA 19-9, and CD-5 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol. 1998;18:93-97
8 Rosai J: Ackerman's surgical pathology. St Louis. Mosby Co., 2004
9 Rosai J, Carcagiu ML, DeLellis RA: Tumors of thyroid gland. In: Atlas of tumor pathology, Fascicle 5, 3rd Series. Washington, DC. Armed Forces Institute of Pathology, 1992
10 Mazzaferri EL: Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553-558   DOI   ScienceOn
11 Orlandi F, Saggiorato E. Pivano G, et al: Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3013-3020
12 Casey MB, Lohse CM, Lloyd RV: Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1. Endocr Pathol. 2003;14:55-60   DOI   ScienceOn
13 Giannini R, Faviana P, Cavinato T, et al: Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid. 2003;13:765-770   DOI   ScienceOn
14 Gharib H: Current evaluation of thyroid nodules. Trends Endocrinol Metab. 1994;5:365-369   DOI   ScienceOn
15 Cvejic D, Savin S, Petrovic I, et al: Galecin-3 expression in papillary microcarcinoma of the thyroid. Histopathology. 2005;47:209-214   DOI   ScienceOn
16 Sack MJ, Astengo-Osuna C, Lin BT, et al: HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol. 1997;10:668-674
17 Aratake Y, Umeki K, Kiyoyama K, et al: Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol. 2002;26:366-372   DOI   ScienceOn
18 Garcia S, Vassko V, Henry JF, De Micco C: Comparison of thyroid peroxidase expression with cellular proliferation in thyroid follicular tumors. Thyroid. 1998;8:745-759   DOI   ScienceOn
19 Li Volsi VA: Surgical pathology of the thyroid. Philadelphia. Saunders, 1990
20 Barondes SH, Cooper DVW, Gitt MA, et al: Galectins: structure and function of a large family of animal lectins. J Biol Chem. 1994;69:20807-20810
21 Prasad ML, Huang Y, Pellegata NS, et al: Hashimoto's thyroiditis with papillary thyroid carcinoma-like nuclear alterations express molecular markers. Histopathology. 2004;45:39-46   DOI   ScienceOn
22 Zeiger MA, Smallridge RC, Clark DP, et al: Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasm. Surgery. 1999;126:1195-1198   DOI   ScienceOn
23 Chow SM, Law SCK, Chan JKC, et al: Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98:31-40   DOI   ScienceOn